CN101810688A - Chinese medicinal composition for treating urinary disease and preparation method thereof - Google Patents
Chinese medicinal composition for treating urinary disease and preparation method thereof Download PDFInfo
- Publication number
- CN101810688A CN101810688A CN200910009364A CN200910009364A CN101810688A CN 101810688 A CN101810688 A CN 101810688A CN 200910009364 A CN200910009364 A CN 200910009364A CN 200910009364 A CN200910009364 A CN 200910009364A CN 101810688 A CN101810688 A CN 101810688A
- Authority
- CN
- China
- Prior art keywords
- group
- capsule
- present
- medicinal composition
- radix astragali
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a Chinese medicinal composition for treating urinary disease and a preparation method thereof. The Chinese medicinal composition is prepared from five gouts of Chinese medicaments comprising pyrrosia leaf, astragalus, kuh-seng, plantain seed and anemone clematis stem. The medicament has the effects of clearing heat and eliminating dampness, disinhibiting urine and freeing strangury, and is mainly used for treating the symptoms such as difficult urination, frequent micturition, urgent urination, dysuria, lower limb edema, acute and chronic glomerulonephritis, pyelonephritis, cystitis, urethritis and the like caused by urinary infection. Compared with the prior art, the medicinal composition has the advantages that: the formula of the medicinal composition is reasonable, and the clinical pharmacodynamical experimental effect is remarkably improved compared with the primary medicinal composition.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition that is used for urologic disease and preparation method thereof, belong to technical field of traditional Chinese medicine pharmacy.
Technical background
Urologic disease is a kind of commonly encountered diseases and frequently-occurring disease, has seriously influenced daily life; Common is urinary tract infection, and doctor trained in Western medicine is mainly used heavy dose of antibiotic and antibacterials, and this type of medicine life-time service easily causes drug dependence and the interior dysbacteriosis of body of antibacterial, and side effect is big.
Existing this sick Chinese patent medicine of treatment is a lot, but curative effect is all not ideal enough with treatment mostly.Prior art: composite shi-wei tablet (" Chinese traditional patent formulation preparation " promulgated by the ministries or commissions of the Central Government 15 WS
3Composite shi-wei tablet under the-B-2940-98 item) be a kind of pure Chinese medicinal preparation, this medicine is being obtained certain curative effect through clinical application for many years aspect the treatment urologic disease.Patent retrieval: 1, Chinese patent communique December in 2004 disclosed name on the 29th and has been called " FUFANG SHIWEI JIAONANG and preparation method thereof ", and publication number is 1557434 patent application; 2, on May 24th, 2006 Chinese patent gazette disclose the name be called " the particulate Preparation method and its quality control technique of a kind of compound pyrrosia leaf ", publication number is 1775234 patent application; 3, on October 25th, 2006 Chinese patent gazette disclose the name be called " a kind of Preparation method and its quality control technique of FUFANG SHIWEI JIAONANG ", publication number is 1850170 patent application; 4, December in 2006 Chinese patent gazette on the 27th discloses name and has been called " preparation method of FUFANG SHIWEI JIAONANG ", and publication number is 1883570 patent application; More than 1,2,4 in four patents all be on the basis of former compound pyrrosia leaf blade technolgy, amount of water and vacuum to have been done refinement, its pharmaceutical effectiveness and composite shi-wei tablet do not have assorted petty difference.Substantial change has been made in the 3rd extraction to former compound pyrrosia leaf blade technolgy Chinese crude drug, and its curative effect and quality can't ensure; More than each herbal medicine raw material weight proportioning four patents and the compound pyrrosia leaf tablet recipe all be: Folium Pyrrosiae 740g, Radix Astragali 740g, Radix Sophorae Flavescentis 740g, Herba Polygoni Avicularis 740g; Our discovery is not ideal enough with the effect of the Chinese patent medicine of this prescription proportioning in actual application.
In the time in recent years, we grope by a large amount of experiments on the basis of original composite shi-wei tablet, find that unexpectedly the De Herba Polygoni Avicularis changes Semen Plantaginis and Caulis Clematidis Armandii into Zhong it after, its clinical pharmacodynamic experiment effect significantly improves, and without any side effects; We routinely the most preferred dosage form made of technology be capsule and granule.
Summary of the invention
The objective of the invention is to: provide a kind of curative effect to treat the Chinese medicine composition of urologic disease more significantly.The present invention is achieved in that according to components by weight percent and calculates, Chinese medicine composition of the present invention be by following materials of weight proportions routinely prepared form: Folium Pyrrosiae 925g, Radix Astragali 925g, Radix Sophorae Flavescentis 925g, Semen Plantaginis 860g, Caulis Clematidis Armandii 860g are prepared from.Described dosage form is capsule and granule.
With capsule of the present invention is example, Pharmacodynamic test of active extract result proves: raw material weight proportioning of the present invention: Folium Pyrrosiae 925g, Radix Astragali 925g, Radix Sophorae Flavescentis 925g, Semen Plantaginis 860g, Caulis Clematidis Armandii 860g are with former invention (composite shi-wei tablet) weight proportion: Folium Pyrrosiae 740g, Radix Astragali 740g, Radix Sophorae Flavescentis 740g, Herba Polygoni Avicularis 740g compare, and results of pharmacodynamic test is significantly increased.Pharmacodynamic test of active extract
Experiment purpose: by pharmacological experiment study to effects such as the antiinflammatory of capsule of the present invention and composite shi-wei tablet, diuresis, human body immunity improving power, treatment glomerulonephritiies, capsule of the present invention and composite shi-wei tablet are compared, observe the power of its pharmacological action.
Test method: capsule of the present invention and composite shi-wei tablet on Carrageenan cause the influence of rat paw edema; To the bullate influence of rat granuloma; Influence to rat urine amount; Influence to Turnover of Mouse Peritoneal Macrophages phagocytic function and immune organ; Effect to cationization bSA glomerulonephritis rat model.
One, trial drug:
A, raw material:
A, capsule group of the present invention: be prepared from by Folium Pyrrosiae 925g, Radix Astragali 925g, Radix Sophorae Flavescentis 925g, Semen Plantaginis 860g, Caulis Clematidis Armandii 860g.
B, composite shi-wei tablet group: be prepared from by Folium Pyrrosiae 740g, Radix Astragali 740g, Radix Sophorae Flavescentis 740g, Herba Polygoni Avicularis 740g.
B, method for making:
Capsule of the present invention is identical with the method for making of composite shi-wei tablet group.
The method for making of a, capsule group of the present invention:
The above five tastes, get Radix Sophorae Flavescentis, Folium Pyrrosiae 893.75g, Radix Astragali 862.5g, Semen Plantaginis 860g and Caulis Clematidis Armandii 830g, decoct with water secondary, for the first time add 10 times of water gagings, decocted 2 hours, add 8 times of water gagings for the second time and decocted 1 hour, filter, filtrate decompression (0.08Mpa, 70 ℃) is concentrated into the thick paste that relative density is 1.30-1.35 (60 ℃), and is standby; Other gets Folium Pyrrosiae 31.25g, Radix Astragali 62.5g, Caulis Clematidis Armandii 30g is ground into fine powder, and with above-mentioned thick paste, mixing, oven dry is pulverized, and granulates, and is encapsulated, makes 1000, promptly gets capsule of the present invention.
The method for making of b, composite shi-wei tablet group:
More than four flavors, get Radix Sophorae Flavescentis, Folium Pyrrosiae 715g, Radix Astragali 690g and Herba Polygoni Avicularis 715g, decoct with water secondary, 2 hours for the first time, 1 hour for the second time, filter, filtrate decompression is concentrated into the thick paste shape; Other gets Folium Pyrrosiae 25g, Radix Astragali 50g, Herba Polygoni Avicularis 25g is ground into fine powder, and with above-mentioned thick paste mixing, oven dry is pulverized, and makes granule, is pressed into 1000, sugar coating, promptly.
Two, test and result:
(1) influence of rat paw edema due to the on Carrageenan
Experiment material
1, animal: Wister kind female rats, body weight 160～180g.
2, medicine: composite shi-wei tablet 2.96g crude drug/sheet; Large, medium and small three the dosage group 4.5g crude drug/grains of capsule of the present invention; 0.5% Sodium Tvlose (CMC-NA) suspension; Carrageenin.Medicine disposes with distilled water before experiment, gastric infusion.
Experimental technique
50 of Wister kind female rats, body weight 160～180g is divided into 5 groups at random, 10 every group.Matched group is irritated 0.5% Sodium Tvlose (CMC-NA) suspension of stomach with volume; Capsule group of the present invention is gastric infusion 1.5,3.0,6.0g crude drug/kg respectively; Composite shi-wei tablet group gastric infusion 6.0g crude drug/kg.Every day 1 time, successive administration 4d, 1h after the last administration, the right back sufficient plantar subcutaneous injection 1% carrageenin solution 0.1ml of every Mus.Respectively at cause scorching before and cause scorching back 1h, 2h, 4h measures sufficient sole of the foot girth (mm) with micrometer during 6h, the record result.And calculate swelling rate % (swelling rate=the cause consistent scorching front foot sole of the foot girth of scorching metapedes sole of the foot girth/cause scorching front foot sole of the foot girth).Carry out significance test between each group.
Experimental result: see Table 1
The influence of rat paw edema due to table 1 on Carrageenan
Compare * P＜0.05 with matched group, * * P＜0.01; With the composite shi-wei tablet group than Δ P＜0.05.
The result shows: rat paw edema has obvious inhibitory action and a certain amount of effect relationship is arranged due to capsule group of the present invention and the composite shi-wei tablet group on Carrageenan, and dosage is big more, acts on obvious more.Big or middle dosage group of capsule of the present invention and composite shi-wei tablet group are causing scorching back 4h, 6h gets the swelling rate and is starkly lower than matched group (P＜0.01), small dose group (1.5g/kg) is causing scorching back 4h, 6h also has remarkable inhibitory action (P＜0.05), heavy dose of group of capsule of the present invention and the composite shi-wei tablet group significant difference (P＜0.05) of having compared during 6h.Capsule group of the present invention is stronger than the anti-acute inflammation effect of composite shi-wei tablet group.
(2) to the bullate influence of rat granuloma
Experiment material
1, animal: Wister kind female rats, body weight 120～150g.
2, medicine: composite shi-wei tablet 2.96g crude drug/sheet; Large, medium and small three the dosage group 4.5g crude drug/grains of capsule of the present invention; Gentamycin.Medicine disposes with distilled water before experiment, gastric infusion.
Experimental technique
50 of Wister kind female rats, body weight 120～150g is divided into 5 groups at random, 10 every group.During test, the rat chesk hair is wiped out in the ether light anaesthesia, and iodine disinfection cuts skin of chest, fills in each one of the aseptic cotton balls of 50mg, skin suture, intramuscular injection gentamycin infection from otch respectively to two forelimb oxters.Postoperative 1h gastric infusion, matched group are irritated the distilled water of stomach with volume; Capsule group of the present invention is gastric infusion 1.5,3.0,6.0g crude drug/kg respectively; Composite shi-wei tablet group gastric infusion 6.0g crude drug/kg.Every day 1 time, successive administration 14d, behind the last administration 1h, rat is put to death in the cervical vertebra dislocation, takes out cotton balls, rejects fat, weighs, and dry 1h in 60 ℃ of baking ovens weighs again, deducts the raw cotton ball weight, calculates granuloma weight, promptly gets granuloma weight in wet base and dry weight.Organize a significance test.
Experimental result: see Table 2
The bullate influence of table 2 pair rat granuloma
Compare * P＜0.05 with matched group, * * P＜0.01; With the composite shi-wei tablet group than Δ P＜0.05.
The result shows: the granuloma that capsule group of the present invention and composite shi-wei tablet group cause cotton balls has the obvious suppression effect.The granulation dry weight of big or middle dosage group of capsule of the present invention and composite shi-wei tablet group has been compared utmost point significant difference (P＜0.01) with matched group, the granulation dry weight of small dose group has been compared significant difference (P＜0.05) with matched group; The granulation weight in wet base of the heavy dose of group of capsule of the present invention, compared utmost point significant difference (P＜0.01) with matched group, in, the granulation weight in wet base of small dose group and composite shi-wei tablet group, compared significant difference (P＜0.05) with matched group, heavy dose of group significant difference (P＜0.05) of having compared with the granulation weight in wet base of composite shi-wei tablet group.Capsule group of the present invention is stronger than the anti-chronic inflammatory disease effect of composite shi-wei tablet group.
(3) to the influence of rat urine amount
Experiment material
1, animal: SD rat male and female half and half, body weight 170～190g.
2, medicine: composite shi-wei tablet 2.96g crude drug/sheet; Large, medium and small three the dosage group 4.5g crude drug/grains of capsule of the present invention; Normal saline.Medicine disposes with distilled water before experiment, gastric infusion.
Experimental technique
50 of SD rats, male and female half and half, body weight 170～190g is divided into 5 groups at random, 10 every group.Water 12h is can't help in the rat fasting before the experiment.Each group is pressed 2ml/100g body weight dosage intraperitoneal injection of saline, and while gastric infusion, matched group are irritated the distilled water of stomach with volume; Capsule group of the present invention is gastric infusion 1.5,3.0,6.0g crude drug/kg respectively; Composite shi-wei tablet group gastric infusion 6.0g crude drug/kg.Administration volume 2ml/100g, 6h is gastric infusion once more, immediately rat is put after the administration to meet urine 24h in people's metabolic cage, surveys total volume of urine.Organize a significance test.
Experimental result: see Table 3
The influence of table 3 pair rat urine amount
Compare * P＜0.05 with matched group, * * P＜0.01; With the composite shi-wei tablet group than Δ P＜0.05.
The result shows: capsule group of the present invention and composite shi-wei tablet group to rat after administration in the 24h urine amount obviously increase, water load rat is had significant diuresis.The big or middle dosage group of capsule of the present invention has been compared utmost point significant difference (P＜0.01) with the composite shi-wei tablet group with matched group; Capsule small dose group of the present invention has been compared significant difference (P＜0.05) with matched group, the heavy dose of group of the capsule of the present invention significant difference (P＜0.05) of having compared with the composite shi-wei tablet group.Capsule group of the present invention is stronger to the diuresis of rat than composite shi-wei tablet group.
(4) to the influence of Turnover of Mouse Peritoneal Macrophages phagocytic function and immune organ
Experiment material
1, animal: SD female mice, body weight 18～20g.
2, medicine: composite shi-wei tablet 2.96g crude drug/sheet; Large, medium and small three the dosage group 4.5g crude drug/grains of capsule of the present invention.
Medicine disposes with distilled water before experiment, gastric infusion.
Experimental technique
The SD female mice, body weight 18～20g is divided into 5 groups at random, 10 every group.Matched group is irritated the distilled water of stomach with volume; Capsule group of the present invention is gastric infusion 3,6,12g crude drug/kg respectively; Composite shi-wei tablet group gastric infusion 12g crude drug/kg.Every day 1 time, successive administration 5d, behind the last administration 1h, mice takes by weighing body weight respectively, lumbar injection 10% sulphur glycollate culture medium 0.8ml/ only induces peritoneal macrophage, after the eyeball blood-letting, takes off cervical vertebra and puts to death, win thymus, spleen is weighed (mg), calculates thymus index and spleen index (mg/g body weight).Hank ' the s liquid that contains heparin with sterilization washes out peritoneal macrophage, and the accent macrophage is 5 * 106/ml, adds 96 orifice plates, and every hole 100 μ l put 37 ℃, 5%, CO
2Cultivate 2h in the incubator, wash culture plate with warm saline, remove last attached cell, add 0.1% dimethyl diaminophenazine chloride, 200 μ l/ holes, put 37 ℃ and hatch 30min again, the extracellular dimethyl diaminophenazine chloride with the normal saline flush away is not engulfed adds cytolysate 200 μ l to every hole again, 4 ℃ of refrigerator overnight are worth in wavelength 492nm place's photometry density (OD) with microplate reader.
Experimental result: see Table 4,5
The influence of table 4 pair mouse immune organ
Compare * P＜0.05 with matched group, * * P＜0.01; With the composite shi-wei tablet group than Δ P＜0.05.
The result shows: capsule group of the present invention and composite shi-wei tablet group do not have influence to the mouse thymus index, and the mouse spleen index is obviously increased.The heavy dose of group of capsule of the present invention has been compared utmost point significant difference (P＜0.01) with matched group; The dosage group has been compared significant difference (P＜0.05) with the composite shi-wei tablet group in the capsule of the present invention with matched group; The heavy dose of group of the capsule of the present invention significant difference (P＜0.05) of having compared with the composite shi-wei tablet group.Capsule group of the present invention is stronger to the immune function of mice effect than composite shi-wei tablet group.
The influence of table 5 pair Turnover of Mouse Peritoneal Macrophages phagocytic function
Compare * P＜0.05 with matched group, * * P＜0.01; With the composite shi-wei tablet group than Δ P＜0.05.
The result shows: capsule group of the present invention and composite shi-wei tablet group have obvious facilitation to the Turnover of Mouse Peritoneal Macrophages phagocytic function.The big or middle dosage group of capsule of the present invention has been compared utmost point significant difference (P＜0.01) with the composite shi-wei tablet group with matched group; Small dose group has been compared significant difference (P＜0.05) with matched group; Heavy dose of group significant difference (P＜0.05) of having compared with the composite shi-wei tablet group.To strengthening the Turnover of Mouse Peritoneal Macrophages vigor, the immunity of body is strong than composite shi-wei tablet group for capsule group of the present invention.
(5) to the effect of cationization bSA (C-BSA) glomerulonephritis rat model
Experiment material
1, animal: SD male rat, body weight 150～200g.
2, medicine: composite shi-wei tablet 2.96g crude drug/sheet; Large, medium and small three the dosage group 4.5g crude drug/grains of capsule of the present invention; Normal saline; BSA (BSA); Anhydrous ethylenediamine (EDA); Carbodiimides (EDC); Incomplete Freund.Medicine disposes with distilled water before experiment, gastric infusion.
Experimental technique
The preparation of cationization bSA (C-BSA)
Add the 500ml DDW with 67mL EDA, slowly add 6mol/L hydrochloric acid 350ml then, transfer pH to 4.75, keep solution at 25 ℃; 5g BSA being dissolved in the 25ml DDW, again this solution slowly being added EDA solution, constantly stir, make constant 25 ℃ of liquid temperature, add 1.8g EDC, behind the 2h is 4.75 acetate buffer solution 30ml cessation reaction with pH, promptly gets the C-BSA solution of isoelectric point, IP raising.With 4 ℃ of DDWs dialysis 72h (per 3 to 5h change water) C-BSA solution, lyophilization, isoelectric point, IP is a C-BSA powder on 8.4, be stored in-20 ℃ standby.
60 of SD male rats, body weight 150～200g is divided into 5 groups at random, 10 every group.Except that matched group, all the other are respectively organized, and rat is got C-BSA 1.0mg respectively and incomplete Freund 0.1ml is mixed, and the subcutaneous rat multi-point injection is immunity in advance.Every rat is injected C-BSA for every after pre-immune 1 week, and in first 1 week of lumbar injection, the dosage of 1d to the 7d is followed successively by 1.0mg, 1.0mg, 1.0mg, 1.5mg, 1.5mg, 2mg, 2mg.The 2nd week rose, tail vein injection 2.5mgC-BSA under sterilising conditions at every turn, and gastric infusion simultaneously, normal group and model group give the normal saline of equal-volume 20ml/kg; Capsule group of the present invention is gastric infusion 1.5,3.0,6.0g crude drug/kg respectively; Composite shi-wei tablet group gastric infusion 6.0g crude drug/kg.Every day 1 time, collect each rat 24h urine at administration 14d and 32d respectively, carry out urine protein content and measure.32d behind the medicine gets blood from the eye socket vein, detects total serum protein, albumin, globulin, cholesterol, serum creatinine and urea nitrogen content.
Experimental result: see Table 6,7,8
The influence of table 6 pair C-BSA nephritis rat model urine protein
Compare * P＜0.05 with model group, * * P＜0.01; With the composite shi-wei tablet group than Δ P＜0.05.
The result shows: capsule group of the present invention and composite shi-wei tablet group can obviously reduce the content of rat urine protein.The big or middle dosage group of capsule of the present invention has been compared utmost point significant difference (P＜0.01) with composite shi-wei tablet with model group; Capsule small dose group of the present invention has been compared significant difference (P＜0.05) with model group; The urine albumen amount of 32d behind the medicine, the heavy dose of group of the capsule of the present invention significant difference (P＜0.05) of having compared with the composite shi-wei tablet group.Capsule group of the present invention is stronger than the effect that composite shi-wei tablet group is eliminated urine protein.
The influence of table 7 pair C-BSA nephritis rat model serum albumin
Compare * P＜0.05 with model group, * * P＜0.01; With the composite shi-wei tablet group than Δ P＜0.05.
The result shows: capsule group of the present invention and composite shi-wei tablet group significantly raise total protein and albumin in the C-BSA nephritis rat model serum, but not remarkable to the globulin influence.Big or middle dosage group of capsule of the present invention and composite shi-wei tablet have been compared significant difference (P＜0.05) to the rising of total protein with model group; The heavy dose of group of capsule of the present invention has been compared utmost point significant difference (P＜0.01) to albuminous rising with model group; Dosage group and composite shi-wei tablet group have been compared significant difference (P＜0.05) to albuminous rising in the capsule of the present invention with model group; To albuminous rising, the heavy dose of group of the capsule of the present invention significant difference (P＜0.05) of having compared with the composite shi-wei tablet group.Capsule group of the present invention is stronger to the effect of C-BSA nephritis rat model serum albumin than composite shi-wei tablet group.
The influence of table 8 pair C-BSA nephritis rat model serum biochemistry index
Compare * P＜0.05 with model group, * * P＜0.01; With the composite shi-wei tablet group than Δ P＜0.05.
The result shows: capsule group of the present invention and composite shi-wei tablet group have significantly reduced the content of C-BSA nephritis rat model cholesterol in serum, creatinine, blood urea nitrogen.Big or middle dosage group of capsule of the present invention and composite shi-wei tablet have been compared significant difference (P＜0.05) to the reduction of creatinine content with model group; The heavy dose of group of capsule of the present invention has been compared utmost point significant difference (P＜0.01) to the reduction of urea nitrogen content with model group; In the capsule of the present invention, small dose group and composite shi-wei tablet group be to the reduction of urea nitrogen content, compared significant difference (P＜0.05) with model group; Big or middle dosage group of capsule of the present invention and composite shi-wei tablet have been compared utmost point significant difference (P＜0.01) to the reduction of cholesterol level with model group; To the reduction of cholesterol level, the heavy dose of group of the capsule of the present invention significant difference (P＜0.05) of having compared with the composite shi-wei tablet group.Capsule group of the present invention is stronger than the effect of composite shi-wei tablet group cholesterol reducing, creatinine, urea nitrogen content.
Acute toxicity testing is the result show: with capsule Cmax of the present invention, maximum volume gastric infusion, successive administration is 3 times in 24h, each 4h at interval, and accumulation medicine total amount reaches 81g crude drug/kg, is equivalent to 109.5 times of clinical plan consumption.In the 7d, mice activity, feed, drainage are all normal after the administration, well-grown, and the hair color light, its average body weight average increases with the prolongation of test period.8d puts to death every mice perusal heart of back dissection, liver, spleen, lung, kidney, brain, thymus, adrenal gland, uterus, stomach, intestinal etc. and does not all find color and paramophia.Show that this capsule does not have acute toxic reaction.
Long term toxicity test is the result show: capsule component of the present invention is that basic, normal, high dosage is respectively 14,28,56g crude drug/kg/d, be equivalent to 18.9,37.8,75.7 times of clinical dosage, gastric infusion is after 12 weeks, capsule of the present invention does not all have tangible influence to general situation, hematological indices, the blood parameters of animal, the yet no abnormal pathological change of system's dissection, organ coefficient and histopathological examination.2 weeks of drug withdrawal are not seen obvious change yet.Capsule of the present invention is not found overt toxicity reaction and delayed toxicity reaction in long term toxicity test.As seen, capsule non-toxic reaction of the present invention, long-term prescription is safe and reliable.Conclusion: capsule group of the present invention and composite shi-wei tablet group can obviously suppress the meat that the foot swelling of carrageenin induced mice and cotton balls cause
Bud is swollen; Has significant diuresis; Promote the Turnover of Mouse Peritoneal Macrophages phagocytic function and obviously increase the mouse spleen index; Obvious suppression the rising of total protein in the C-BSA nephritis rat model serum and albuminous reduction and cholesterol, creatinine, blood urea nitrogen, the content of rat urine protein is obviously reduced.The result shows, capsule of the present invention is stronger than effects such as the antiinflammatory of composite shi-wei tablet, diuresis, human body immunity improving power, treatment glomerulonephritiies, and capsule pharmacological action of the present invention is better than composite shi-wei tablet.
Clinical trial:
Clinical observation patient 293 examples of the present invention, outpatient's 234 examples wherein, inpatient's 59 examples.Wherein treat acute and chronic glomerulonephritis patient 64 examples; Pyelonephritis, cystitis, urethritis patient be totally 229 examples.The present invention has better curative effect to acute and chronic brightic treatment, can obviously reduce urine protein or turns out cloudy, and alleviates patient's edema.Pyelonephritis, cystitis, urethritis patient's urine number of times is normal, and dysurea alleviates or disappears, and on inspection, inflammation disappears.Clinical observation result shows: total effective rate of the present invention is 97.5%; The heat clearing and damp drying of this product is described, the exact efficacy of inducing diuresis for treating stranguria syndrome in the clinical observation process, does not find that the patient has untoward reaction and anaphylaxis, illustrates that this product is safe.
The specific embodiment of the invention:
Prescription:
Folium Pyrrosiae 925g Radix Astragali 925g Radix Sophorae Flavescentis 925g Semen Plantaginis 860g Caulis Clematidis Armandii 860g
1, the preparation method of capsule of the present invention:
The above five tastes, get Radix Sophorae Flavescentis, Folium Pyrrosiae 893.75g, Radix Astragali 862.5g, Semen Plantaginis 860g and Caulis Clematidis Armandii 830g, decoct with water secondary, for the first time add 10 times of water gagings, decocted 2 hours, add 8 times of water gagings for the second time and decocted 1 hour, filter, filtrate decompression (0.08Mpa, 70 ℃) is concentrated into the thick paste that relative density is 1.30-1.35 (60 ℃), and is standby; Other gets Folium Pyrrosiae 31.25g, Radix Astragali 62.5g, Caulis Clematidis Armandii 30g is ground into fine powder, and with above-mentioned thick paste, mixing, oven dry is pulverized, and granulates, and is encapsulated, makes 1000, promptly gets capsule of the present invention.
2, the preparation method of granule of the present invention:
The above five tastes, get Radix Sophorae Flavescentis, Folium Pyrrosiae 893.75g, Radix Astragali 862.5g, Semen Plantaginis 860g and Caulis Clematidis Armandii 830g, decoct with water secondary, for the first time add 10 times of water gagings, decocted 2 hours, add 8 times of water gagings for the second time and decocted 1 hour, filter, filtrate decompression (0.08Mpa, 70 ℃) is concentrated into the thick paste that relative density is 1.30-1.35 (60 ℃), and is standby; Other gets Folium Pyrrosiae 31.25g, Radix Astragali 62.5g, Caulis Clematidis Armandii 30g is ground into fine powder, and with above-mentioned thick paste, mixing, oven dry is pulverized, and adds an amount of dextrin, granulate, and drying, granulate is made granule 1000g, and pack promptly gets granule of the present invention.
Claims (5)
1. Chinese medicine composition that is used for urologic disease, it is characterized in that: calculate according to components by weight percent: it is prepared from by Folium Pyrrosiae 600-1200g, Radix Astragali 600-1200g, Radix Sophorae Flavescentis 600-1200g, Semen Plantaginis 600-1000g, Caulis Clematidis Armandii 600-1000g.
2. according to the described Chinese medicine composition of claim 1, it is characterized in that: it is by Folium Pyrrosiae 925g, Radix Astragali 925g, Radix Sophorae Flavescentis 925g, Semen Plantaginis 860g, Caulis Clematidis Armandii 860g.
3. the Chinese medicine composition of stating according to claim 1 or 2, it is characterized in that: described optimal formulation is capsule and granule.
4. according to the preparation method of the described Chinese medicinal composition capsules agent of claim 3, it is characterized in that:
The above five tastes, get Radix Sophorae Flavescentis, Folium Pyrrosiae 893.75g, Radix Astragali 862.5g, Semen Plantaginis 860g and Caulis Clematidis Armandii 830g, decoct with water secondary, for the first time add 10 times of water gagings, decocted 2 hours, add 8 times of water gagings for the second time and decocted 1 hour, filter, filtrate decompression (0.08Mpa, 70 ℃) is concentrated into the thick paste that relative density is 1.30-1.35 (60 ℃), and is standby; Other gets Folium Pyrrosiae 31.25g, Radix Astragali 62.5g, Caulis Clematidis Armandii 30g is ground into fine powder, and with above-mentioned thick paste, mixing, oven dry is pulverized, and granulates, and is encapsulated, makes 1000, promptly gets capsule of the present invention.
5. according to the preparation method of the described Chinese medicinal composition granules of claim 3, it is characterized in that:
The above five tastes, get Radix Sophorae Flavescentis, Folium Pyrrosiae 893.75g, Radix Astragali 862.5g, Semen Plantaginis 860g and Caulis Clematidis Armandii 830g, decoct with water secondary, for the first time add 10 times of water gagings, decocted 2 hours, add 8 times of water gagings for the second time and decocted 1 hour, filter, filtrate decompression (0.08Mpa, 70 ℃) is concentrated into the thick paste that relative density is 1.30-1.35 (60 ℃), and is standby; Other gets Folium Pyrrosiae 31.25g, Radix Astragali 62.5g, Caulis Clematidis Armandii 30g is ground into fine powder, and with above-mentioned thick paste, mixing, oven dry is pulverized, and adds an amount of dextrin, granulate, and drying, granulate is made granule 1000g, and pack promptly gets granule of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100093645A CN101810688B (en) | 2009-02-20 | 2009-02-20 | Chinese medicinal composition for treating urinary disease and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100093645A CN101810688B (en) | 2009-02-20 | 2009-02-20 | Chinese medicinal composition for treating urinary disease and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101810688A true CN101810688A (en) | 2010-08-25 |
| CN101810688B CN101810688B (en) | 2011-08-24 |
Family
ID=42618148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100093645A Active CN101810688B (en) | 2009-02-20 | 2009-02-20 | Chinese medicinal composition for treating urinary disease and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101810688B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102258649A (en) * | 2011-08-18 | 2011-11-30 | 荣成市商贸城卫生所 | Chinese medicinal composition for treating infant frequent micturition |
| CN102423423A (en) * | 2011-11-01 | 2012-04-25 | 文登市口腔医院米山路口腔诊所 | Traditional Chinese medicine for treating urinary tract infection |
| CN107669718A (en) * | 2017-09-30 | 2018-02-09 | 广东罗浮山国药股份有限公司 | A kind of application of Chinese medicine composition in the medicine for preparing treatment acute urethritis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1557434A (en) * | 2004-02-10 | 2004-12-29 | 贵阳济仁堂药业有限公司 | Compound capsule of petioled pyrrosia frond and its preparing process |
| CN100581563C (en) * | 2006-05-30 | 2010-01-20 | 湖南长沙宝鉴生物工程有限公司 | Method for preparing compound pyrrosia leaf capsule |
-
2009
- 2009-02-20 CN CN2009100093645A patent/CN101810688B/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102258649A (en) * | 2011-08-18 | 2011-11-30 | 荣成市商贸城卫生所 | Chinese medicinal composition for treating infant frequent micturition |
| CN102423423A (en) * | 2011-11-01 | 2012-04-25 | 文登市口腔医院米山路口腔诊所 | Traditional Chinese medicine for treating urinary tract infection |
| CN107669718A (en) * | 2017-09-30 | 2018-02-09 | 广东罗浮山国药股份有限公司 | A kind of application of Chinese medicine composition in the medicine for preparing treatment acute urethritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101810688B (en) | 2011-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104366636B (en) | A kind of Gynura procumbens (Lour.) Merr. compound formulation and preparation method and application | |
| CN101940620B (en) | Medicinal composition for treating diabetes mellitus and application thereof | |
| CN104524110A (en) | Traditional Chinese medicine composition with functions of tonifying spleen and clearing damp | |
| CN104068284A (en) | Compound feed used for curing gosling plague and preparation method of compound feed | |
| CN101181395B (en) | Medicine preparations for curing dermatosis and preparation method thereof | |
| CN102754754B (en) | Whole oat type piglet compound feed and preparation method thereof | |
| CN100443112C (en) | Medicine for treating gout and gout arthritis | |
| CN105997985A (en) | Application of marihuana extract in preparation of gout treating medicine | |
| CN104815192A (en) | Pharmaceutical composition for treating hypertension and application of pharmaceutical composition | |
| CN101810688B (en) | Chinese medicinal composition for treating urinary disease and preparation method thereof | |
| CN101843814A (en) | Chinese medicinal compound preparation for treating gout and hyperuricemia and preparation method thereof | |
| CN101884749B (en) | Particle for eliminating turbidity and treating arthralgia | |
| CN101214341B (en) | Medicine preparation for curing psoriasis and preparation thereof | |
| WO2005074952A1 (en) | Chinese medicine for treatment of irritable bowel sysndrome and the preparation thereof | |
| CN110326788A (en) | A kind of bitter buckwheat d-chiro-inositol compound hypoglycemic tabletting and preparation method thereof | |
| CN100579564C (en) | Medicine for curing gout and its preparing method | |
| CN107412626A (en) | A kind of invigorating the spleen to clear away damp pathogen composition and its processing method and the application in clearing damp anti-trioxypurine product | |
| CN101011457A (en) | Traditional Chinese medicine composition with immunological enhancement function | |
| CN100509017C (en) | Medicine for treating biliary tract infection and prepn process thereof | |
| CN103933154B (en) | A kind of Chinese medicine composition treating goat and preparation method thereof | |
| CN103120721B (en) | Chinese medicinal composition for treating wind-heat common cold and preparation method and application thereof | |
| CN101045116B (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN101406556B (en) | Chinese medicine preparation for treating acute prostatitis, prostatic hyperplasia and preparation method thereof | |
| CN103735710A (en) | Traditional Chinese medicine composition for treating recessive mastitis of dairy cows and preparation method thereof | |
| CN102579947A (en) | Chinese medicinal composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |